Optimi Health Corp. OPTH
Set alert
2.41 USD -0.19 -7.31%
At close · Oct 30
2.60 +0.19 +7.88%
After hours · Oct 30, 4:00 PM ET
2.02 Day range 2.60
2.41 52-week range 6.08
- YTD
- -60.36%
- 1 year
- -60.36%
- Open
- 2.58
- Prev close
- 2.60
- Mkt cap
- 13.80M
- Vol
- 59.41K
- Avg vol
- 39.02K
- EPS
- -1.56
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.02
- High
- 2.60
2Y chart
Events in this range
- May 20, 2026Split: 1 for 30
Signals (18)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 2, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| RSI: Oversold | Jun 11, 2026 | 4 months ago |
Financials — quick view
OPTH Revenue — quarterly 140.20K
OPTH Net income — quarterly -2.40M
OPTH EPS — quarterly -0.56
News
- Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
- Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027
- Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
- Optimi Health to Present at the ThinkEquity Conference
- Optimi Health Appoints Melanie Pump to Board of Directors
- Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Jumps 109.1%
- Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia
- Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
- Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
- Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
Your note
Sign in to keep a note on OPTH — it syncs with the Stock Master app.